noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Healthcare

Oncodesign Precision Medicine SA

12/29/2025 | Press release | Distributed by Public on 12/29/2025 11:01

Oncodesign Precision Medicine and Navigo Proteins announce the end of their collaboration in the development of radiotheranostics

Dijon, France, December, 29, 2025, at 6:00 pm CET - Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin® technology platform, jointly announce the termination of their collaboration agreement signed in May 2024.

Oncodesign Precision Medicine SA published this content on December 29, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on December 29, 2025 at 17:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]